Advances in Transdermal Drug Delivery System for Treating Breast Cancer
WANG Xue-jiao1, ZHAO Feng1*, MA Yin-ling1,2, WU Xian1, CAO De-ying1*
1. Department of Pharmaceutics, School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, China; 2. Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051, China
Abstract：Breast cancer is still a major disease threatening women's health. In recent years, some progress has been made in transdermal drug delivery system for breast cancer treatment. New transdermal drug delivery strategies, including microemulsion, liposomes, hydrogels and microneedles, not only make the clinical efficacy of drugs for breast cancer more significant, but also make the painless, self-contained treatment more acceptable to patients. Therefore, this paper summarizes the characteristics of percutaneous drug delivery system for breast cancer, and could make an outlook for the future of percutaneous drug delivery for breast cancer.
王雪娇, 赵锋, 马银玲, 吴献, 曹德英. 经皮给药系统治疗乳腺癌的研究进展[J]. 中国药学杂志, 2022, 57(10): 779-783.
WANG Xue-jiao, ZHAO Feng, MA Yin-ling, WU Xian, CAO De-ying. Advances in Transdermal Drug Delivery System for Treating Breast Cancer. Chinese Pharmaceutical Journal, 2022, 57(10): 779-783.
HARBECK N, GNANT M.[J]. Lancet, 2017, 389(10074): 1134-1150.
[2]
AKRAM M, IQBAL M, DANIYAL M, et al. Awareness and current knowledge of breast cancer[J]. Biol Res, 2017, 50(1): 33.DOI:10.1186/s40659-017-0140-9
[3]
SHIEH Y, TICE J A. Medications for primary prevention of breast cancer[J]. JAMA, 2020, 324(3): 291-292.
[4]
GRAHAM D, DINOME M L, GANZ P A. Breast cancer risk-reducing medications[J]. JAMA, 2020, 324(3): 310.DOI:10.1001/jama.2020.11784
[5]
NOROUZI M, NAZARI B, MILLER D W. Injectable hydrogel-based drug delivery systems for local cancer therapy[J]. Drug Discov Today, 2016, 21(11): 1835-1849.
[6]
WONG R, GEYER S, WENINGER W, et al. The dynamic anatomy and patterning of skin[J]. Exp Dermatol, 2016, 25(2): 92-98.
[7]
JESINGER R A. Breast anatomy for the interventionalist[J]. Tech Vasc Interv Radiol, 2014, 17(1): 3-9.
[8]
LEE O, IVANCIC D, ALLU S, et al. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation[J]. Cancer Chemother Pharmacol, 2015, 76(6): 1235-1246.
[9]
BATHARA M, DATE T, CHAUDHARI D, et al. Exploring the promising potential of high permeation vesicle-mediated localized transdermal delivery of docetaxel in breast cancer to overcome the limitations of systemic chemotherapy[J]. Mol Pharm, 2020, 17(7): 2473-2486.
[10]
RUBY P K, PATHAK S M, AGGARWAL D. Critical attributes of transdermal drug delivery system(TDDS)—a generic product development review[J]. Drug Dev Ind Pharm, 2014, 40(11): 1421-1428.
[11]
WOKOVICH A M, PRODDUTURI S, DOUB W H, et al. Transdermal drug delivery system(TDDS) adhesion as a critical safety, efficacy and quality attribute[J]. Eur J Pharm Biopharm, 2006, 64(1): 1-8.
[12]
LIU C H, CHANG F Y. Development and characterization of eucalyptol microemulsions for topic delivery of curcumin[J]. Chem Pharm Bull(Tokyo), 2011, 59(2): 172-178.
[13]
SHENDE P, VAIDYA J, GAUD R S. Pharmacotherapeutic approaches for transportation of anticancer agents via skin[J]. Artif Cells Nanomed Biotechnol, 2018, 46(sup3): S423-S433.
[14]
FISUSI F A, AKALA E O. Drug combinations in breast cancer therapy[J]. Pharm Nanotechnol, 2019, 7(1): 3-23.
[15]
BOMMAREDDY A, KNAPP K, NEMETH A, et al. Alpha-santalol, a component of sandalwood oil inhibits migration of breast cancer cells by targeting the beta-catenin pathway[J]. Anticancer Res, 2018, 38(8): 4475-4480.
[16]
DAVE K, ALSHARIF F M, ISLAM S, et al. Chemoprevention of breast cancer by transdermal delivery of alpha-santalol through breast skin and mammary papilla(Nipple)[J]. Pharm Res, 2017, 34(9): 1897-1907.
[17]
YUANYUAN G, WEIFEN Z, TONGYI S. Local transdermal delivery of 10, 11-methylenedioxycamptothecin by nanoemulsion for breast cancer prevention[J]. J Controlled Release, 2017, 259.DOI:10.1016/j.jconrel.2017.03.356
[18]
WADKINS R M, POTTER P M, VLADU B, et al. Water soluble 20(S)-glycinate esters of 10, 11-methylenedioxycamptothecins are highly active against human breast cancer xenografts[J]. Cancer Res, 1999, 59(14): 3424-3428.
[19]
SUNDRALINGAM U, CHAKRAVARTHI S, RADHAKRISHNAN A K, et al. Efficacy of emu oil transfersomes for local transdermal delivery of 4-OH tamoxifen in the treatment of breast cancer[J]. Pharmaceutics, 2020, 12(9).DOI:10.3390/pharmaceutics12090807
[20]
LIN Y L, CHEN C H, WU H Y, et al. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex[J]. J Nanobiotechnol, 2016, 14: 11.DOI:10.1186/s12951-016-0163-3
[21]
MAHMOOD S, TAHER M, MANDAL U K. Experimental design and optimization of raloxifene hydrochloride loaded nanotransfersomes for transdermal application[J]. Int J Nanomed, 2014, 9: 4331-4346.
[22]
SUNDRALINGAM U, MUNIYANDY S, RADHAKRISHNAN A K, et al. Ratite oils for local transdermal therapy of 4-OH tamoxifen: development, characterization, and ex vivo evaluation[J]. J Liposome Res, 2020,1-13.DOI:10.1080/08982104.2020.1777155
[23]
ABDEL-HAFEZ S M, HATHOUT R M, SAMMOUR O A. Curcumin-loaded ultradeformable nanovesicles as a potential delivery system for breast cancer therapy[J]. Colloids Surf B Biointerfaces, 2018, 167: 63-72.
[24]
ATLAN M, NEMAN J. Targeted transdermal delivery of curcumin for breast cancer prevention[J]. Int J Environ Res Public Health, 2019, 16(24).DOI:10.3390/ijerph16244949
[25]
TAJBAKHSH A, HASANZADEH M, REZAEE M, et al. Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways[J]. J Cell Physiol, 2018, 233(3): 2183-2192.
[26]
HUANG Q, ZOU Y, ARNO M C, et al. Hydrogel scaffolds for differentiation of adipose-derived stem cells[J]. Chem Soc Rev, 2017, 46(20): 6255-6275.
[27]
PUSHPALATHA R, SELVAMUTHUKUMAR S, KILIMOZHI D. Cyclodextrin nanosponge based hydrogel for the transdermal co-delivery of curcumin and resveratrol: Development, optimization, in vitro and ex vivo evaluation[J]. J Drug Deliv Sci Technol, 2019, 52.DOI:10.1016/j.jddst.2019.04.025
[28]
MAJDALAWIEH A F, MANSOUR Z R. Sesamol, a major lignan in sesame seeds(Sesamum indicum): Anti-cancer properties and mechanisms of action[J]. Eur J Pharmacol, 2019, 855:75-89.
[29]
ELMASRY S R A, HATHOUT R M A B, ABDEL-HALIM M C, et al. In vitro transdermal delivery of sesamol using oleic acid chemically-modified gelatin nanoparticles as a potential breast cancer medication(Article)[J]. J Drug Deliv Sci Technol, 2018,48:30-39.
[30]
HAO Y, LI W, ZHOU X, et al. Microneedles-based transdermal drug delivery systems: A review[J]. J Biomed Nanotechnol, 2017, 13(12): 1581-1597.
[31]
WAGHULE T, SINGHVI G, DUBEY S K, et al. Microneedles: A smart approach and increasing potential for transdermal drug delivery system[J]. Biomed Pharmacother, 2019, 109: 1249-1258.
[32]
MOFFATT K, WANG Y, RAJ S T, et al. Microneedles for enhanced transdermal and intraocular drug delivery[J]. Curr Opin Pharmacol, 2017, 36: 14-21.
[33]
GAO X, PATEL M G, BAKSHI P, et al. Enhancement in the transdermal and localized delivery of honokiol through breast tissue[J]. AAPS PharmSciTech, 2018, 19(8): 3501-3511.
[34]
LI J, HAO Q, CAO W, et al. Celecoxib in breast cancer prevention and therapy[J]. Cancer Manag Res, 2018, 10: 4653-4667.
[35]
MOJEIKO G, de BRITO M, SALATA G C, et al. Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer[J]. Int J Pharm, 2019, 560: 365-376.
[36]
FU J J, LI C W, LIU Y, et al. The microneedles carrying cisplatin and IR820 to perform synergistic chemo-photodynamic therapy against breast cancer[J]. J Nanobiotechnol, 2020, 18(1): 146.
[37]
CHABLANI L, TAWDE S A, AKALKOTKAR A, et al. Evaluation of a particulate breast cancer vaccine delivered via skin[J]. AAPS J, 2019, 21(2): 12.
[38]
ABU S T, SAMEC M, LISKOVA A, et al. Paclitaxel's mechanistic and clinical effects on breast cancer[J]. Biomolecules, 2019, 9(12):789.DOI:10.33901biom9120789
[39]
MEHNATH S, CHITRA K, KARTHIKEYAN K, et al. Localized delivery of active targeting micelles from nanofibers patch for effective breast cancer therapy[J]. Int J Pharm, 2020, 584: 119412.DOI:10.1016/j.ijpharm.2020.119412
[40]
TIAN W, XIE X J, CAO P L. Magnoflorine improves sensitivity to doxorubicin(DOX) of breast cancer cells via inducing apoptosis and autophagy through AKT/mTOR and p38 signaling pathways[J]. Biomed Pharmacother, 2020, 121: 109139.DOI:10.1016/j.biopha.2019.109139
[41]
LK Z, DU S W, XZ W, et al. Bacterial cellulose based composites enhanced transdermal drug targeting for breast cancer treatment[J]. Chem Eng J, 2019,370:749-759.
2022, Vol. 57 
